Corporate Communications
Week ending August 23, 2026
1. This week's narrative in one paragraph
AI assistants are describing Cosentyx in broadly neutral, patient-centered terms: a targeted IL-17A biologic that can be effective for psoriasis and related inflammatory conditions, with practical differences in dosing, administration, insurance access, and side-effect considerations. The comparison narrative is highly competitive, with Humira, Enbrel, Stelara, and Taltz frequently named. Some answers still use favorable or ranking language such as “rapid,” “best,” “stronger,” or “superior,” although most explicitly advise against treating Cosentyx as universally better. Safety topics are prominent—especially infection risk, candidiasis, tuberculosis, inflammatory bowel disease, and pregnancy—making the overall story more safety-qualified than promotional.
2. Anything with public-story potential
-
“AI assistants give inconsistent answers about Cosentyx safety warnings.” On the boxed-warning question, most answers say Cosentyx has no boxed warning, while one uses “boxed-warning-level guidance.” This could become a screenshot-driven trust story, even though the underlying issue is inconsistent terminology rather than evidence of a new safety event.
-
“AI assistants give conflicting information about Cosentyx-related inflammatory bowel disease risk.” IBD is mentioned inconsistently across comparisons with Taltz, Humira, Enbrel, and Stelara. This is particularly visible in patient-facing comparisons and could be amplified by an advocacy group or patient post.
-
“Can a pharmacy substitute Cosentyx?” Biosimilar/generic discussion rose from 9 to 11 mentions, and answers vary in how confidently they describe substitution. The likely public framing would be confusion about whether a pharmacy can replace a branded biologic without clear patient understanding.
3. Topics with a public-attention history
Access and insurance are recurring in switching answers, especially prior authorization and coverage, but there is no clear new pricing controversy this week. Biosimilar substitution remains a live public-interest topic and merits monitoring. Off-label discussion rose from 1 to 3 mentions, though the absolute signal remains small. Compounding does not appear in this week’s tagged data. Infection, IBD, pregnancy, and infant live-vaccine questions remain sensitive safety narratives, but the data show no new event—only continued visibility and answer variation.
4. Trajectory
The overall pattern is recurring and broadly stable, with modest building in safety visibility. Inconsistency flags increased from 24 to 26, below the four-week highs of 27–28. Infection-risk mentions rose from 78 to 87, IBD from 32 to 40, and pregnancy/lactation from 15 to 19. Competitor mentions also increased, led by Humira (18), Enbrel (17), Stelara (16), and Taltz (16), though response volume rose from 120 to 140. The boxed-warning inconsistency is recurring rather than new; substitution and off-label signals are rising but remain limited.
5. Recommended actions
- Prepare a short holding line on safety-warning terminology and inconsistent AI answers; coordinate with PV and Medical Affairs.
- Prepare a concise public FAQ on biologic substitution and biosimilars, emphasizing that pharmacy rules vary by jurisdiction and prescription.
- Align neutral comparison language for Cosentyx versus major competitors, avoiding “stronger,” “best,” or universal superiority framing.
- Monitor pregnancy/infant-vaccine and IBD narratives weekly; no proactive response unless volume or inconsistency increases.